Nuvo Pharmaceuticals acquires global rights for Head Lice Treatment

Nuvo Pharmaceuticals announced that it had acquired the global rights for Resultz, a head lice treatment from Piedmont Pharmaceuticals.

A report published in a Pharmaceutical Investment Network on the 4th of January 2018 revealed that Resultz is currently approved for sale under its European Conformity (CE) mark as a class 1 medical device. This transaction between Nuvo Pharmaceuticals and Piedmont Pharmaceuticals will include existing royalty streams in Royalty Markets and all product and intellectual property.

The head lice treatment, Resultz is not yet partnered or launched in all remaining E.U. territories including the key markets of Germany, Italy, the Netherlands, Scandinavia and Greece. Resultz is also not yet been approved in most of the other world markets, including the Middle East and Africa, Latin America and Asia Pacific (outside of Japan and Australia).

With a global head lice prevalence of approximately 6%, the market opportunity for Resultz in all non-Royalty Markets is attractive and growing.